Revolution Medicines (RVMD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Critical company metrics and information
Share Price
$47.76Market Cap
$8.03 BillionTotal Outstanding Shares
168.22 Million SharesTotal Employees
490Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.revmed.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $924.96 Million |
Net Cash Flow From Investing Activities | $-541.89 Million |
Net Cash Flow From Financing Activities, Continuing | $924.96 Million |
Net Cash Flow From Operating Activities | $-539.71 Million |
Net Cash Flow From Investing Activities, Continuing | $-541.89 Million |
Net Cash Flow | $-156.64 Million |
Net Cash Flow From Operating Activities, Continuing | $-539.71 Million |
Net Cash Flow, Continuing | $-156.64 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $742,000.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-567.06 Million |
Net Income/Loss | $-567.06 Million |
Diluted Earnings Per Share | $-3.66 |
Operating Income/Loss | $-653.20 Million |
Income/Loss From Continuing Operations Before Tax | $-566.72 Million |
Research and Development | $552.61 Million |
Net Income/Loss Attributable To Parent | $-567.06 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations After Tax | $-567.06 Million |
Diluted Average Shares | $341.23 Million |
Operating Expenses | $653.94 Million |
Income Tax Expense/Benefit | $343,000.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $-3.66 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Average Shares | $341.23 Million |
Nonoperating Income/Loss | $86.48 Million |
Other Operating Expenses | $96.33 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Intangible Assets | $56.94 Million |
Current Liabilities | $110.86 Million |
Liabilities | $196.69 Million |
Assets | $1.76 Billion |
Noncurrent Assets | $183.86 Million |
Fixed Assets | $24.81 Million |
Equity | $1.57 Billion |
Liabilities And Equity | $1.76 Billion |
Current Assets | $1.58 Billion |
Other Non-current Assets | $102.11 Million |
Equity Attributable To Parent | $1.57 Billion |
Noncurrent Liabilities | $85.83 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $24.46 Million |
Other Current Liabilities | $86.41 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.